This study describes the innovation techniques that Eli Lily has implemented in its June 2009 Phenotypic Drug Discovery (PD2), and describing their expanded open-innovation platform. This process now permits outside scientists to deposit molecules and have them tested free of charge. This new venture is called TD(2). Eli Lily is particularly focused on the fields of endocrinology, neuroscience, oncology and cardiovascular diseases. The Open-Innovation Drug Discovery Innovation combines the existing PD2 platform with three new programs.
The author depicts the collaboration of the University of California San Diego and Pfizer’s Centers for Therapeutic Innovation (CTI). The collaboration between the two innovators will put more than $50 million in the university coiffures. Under the terms of the collaboration, Pfizer agrees to share it library of antibodies and technologies. This is an expansion of the 2010 Clinical and Translational Research Institute (CTRI) initiative.